The global Inhalation CDMO market was valued at US$ 3472 million in 2025 and is anticipated to reach US$ 7226 million by 2032, at a CAGR of 11.2% from 2026 to 2032.

Inhalation CDMO Market

Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.

Inhalation Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers that assist pharmaceutical companies in the development and production of inhalation products, such as inhalers and nebulizers. The market for inhalation CDMOs is growing steadily, driven by the increasing prevalence of respiratory diseases like asthma and COPD, and the rising demand for complex inhalation therapies. The North America and Europe are the major sales regions, although significant growth is also expected in Asia-Pacific. Market opportunities lie in the development of novel drug delivery systems, biologics, and personalized medicine, while challenges include regulatory complexities and the high cost of development. Future product trends point towards the integration of digital health technologies and sustainable packaging solutions in inhalation products.

This report delivers a comprehensive overview of the global Inhalation CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Inhalation CDMO. The Inhalation CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Inhalation CDMO market comprehensively. Regional market sizes by Type, by Application, by Technology Platform, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Inhalation CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Inhalation CDMO Market Report

Report Metric	Details
Report Name	Inhalation CDMO Market
Accounted market size in 2025	US$ 3472 in million
Forecasted market size in 2032	US$ 7226 million
CAGR	11.2%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Metered Dose Inhalers (MDIs) Dry Powder Inhalers (DPIs) Soft Mist Inhalers (SMIs) Others
Segment by Technology Platform	Propellant-based Inhalation Technology Platform Dry Powder Inhalation Technology Platform Nebulization Technology Platform Combined Inhalation Technology Platform
Segment by Service Stage	Preclinical Development CDMO Clinical Stage CDMO Commercial Production CDMO One-stop Full-cycle CDMO
Segment by Application	Commercial Academic Research Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, Vectura, Iconovo, CritiTech, Hovione, Recipharm, Aptar Pharma, Kindeva, Sanner, Particle Sciences, Experic, Enteris Biopharma, Catalent, HCmed, Ritedose, Bespak, Proveris, Bend Bioscience, Renejix
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Technology Platform, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Inhalation CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Inhalation CDMO Market growing?

Ans: The Inhalation CDMO Market witnessing a CAGR of 11.2% during the forecast period 2026-2032.

What is the Inhalation CDMO Market size in 2032?

Ans: The Inhalation CDMO Market size in 2032 will be US$ 7226 million.

Who are the main players in the Inhalation CDMO Market report?

Ans: The main players in the Inhalation CDMO Market are Lonza, Vectura, Iconovo, CritiTech, Hovione, Recipharm, Aptar Pharma, Kindeva, Sanner, Particle Sciences, Experic, Enteris Biopharma, Catalent, HCmed, Ritedose, Bespak, Proveris, Bend Bioscience, Renejix

What are the Application segmentation covered in the Inhalation CDMO Market report?

Ans: The Applications covered in the Inhalation CDMO Market report are Commercial, Academic Research, Others

What are the Type segmentation covered in the Inhalation CDMO Market report?

Ans: The Types covered in the Inhalation CDMO Market report are Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Soft Mist Inhalers (SMIs), Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Inhalation CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Metered Dose Inhalers (MDIs)

1.2.3 Dry Powder Inhalers (DPIs)

1.2.4 Soft Mist Inhalers (SMIs)

1.2.5 Others

1.3 Market by Technology Platform

1.3.1 Global Inhalation CDMO Market Size Growth Rate by Technology Platform: 2021 vs 2025 vs 2032

1.3.2 Propellant-based Inhalation Technology Platform

1.3.3 Dry Powder Inhalation Technology Platform

1.3.4 Nebulization Technology Platform

1.3.5 Combined Inhalation Technology Platform

1.4 Market by Service Stage

1.4.1 Global Inhalation CDMO Market Size Growth Rate by Service Stage: 2021 vs 2025 vs 2032

1.4.2 Preclinical Development CDMO

1.4.3 Clinical Stage CDMO

1.4.4 Commercial Production CDMO

1.4.5 One-stop Full-cycle CDMO

1.5 Market by Application

1.5.1 Global Inhalation CDMO Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Commercial

1.5.3 Academic Research

1.5.4 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Inhalation CDMO Market Perspective (2021–2032)

2.2 Global Inhalation CDMO Growth Trends by Region

2.2.1 Global Inhalation CDMO Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Inhalation CDMO Historic Market Size by Region (2021–2026)

2.2.3 Inhalation CDMO Forecasted Market Size by Region (2027–2032)

2.3 Inhalation CDMO Market Dynamics

2.3.1 Inhalation CDMO Industry Trends

2.3.2 Inhalation CDMO Market Drivers

2.3.3 Inhalation CDMO Market Challenges

2.3.4 Inhalation CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Inhalation CDMO Players by Revenue

3.1.1 Global Top Inhalation CDMO Players by Revenue (2021–2026)

3.1.2 Global Inhalation CDMO Revenue Market Share by Players (2021–2026)

3.2 Global Top Inhalation CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Inhalation CDMO Revenue

3.4 Global Inhalation CDMO Market Concentration Ratio

3.4.1 Global Inhalation CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Inhalation CDMO Revenue in 2025

3.5 Global Key Players of Inhalation CDMO Head Offices and Areas Served

3.6 Global Key Players of Inhalation CDMO, Products and Applications

3.7 Global Key Players of Inhalation CDMO, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Inhalation CDMO Breakdown Data by Type

4.1 Global Inhalation CDMO Historic Market Size by Type (2021–2026)

4.2 Global Inhalation CDMO Forecasted Market Size by Type (2027–2032)

5 Inhalation CDMO Breakdown Data by Application

5.1 Global Inhalation CDMO Historic Market Size by Application (2021–2026)

5.2 Global Inhalation CDMO Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Inhalation CDMO Market Size (2021–2032)

6.2 North America Inhalation CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Inhalation CDMO Market Size by Country (2021–2026)

6.4 North America Inhalation CDMO Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Inhalation CDMO Market Size (2021–2032)

7.2 Europe Inhalation CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Inhalation CDMO Market Size by Country (2021–2026)

7.4 Europe Inhalation CDMO Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Inhalation CDMO Market Size (2021–2032)

8.2 Asia-Pacific Inhalation CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Inhalation CDMO Market Size by Region (2021–2026)

8.4 Asia-Pacific Inhalation CDMO Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Inhalation CDMO Market Size (2021–2032)

9.2 Latin America Inhalation CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Inhalation CDMO Market Size by Country (2021–2026)

9.4 Latin America Inhalation CDMO Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Inhalation CDMO Market Size (2021–2032)

10.2 Middle East & Africa Inhalation CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Inhalation CDMO Market Size by Country (2021–2026)

10.4 Middle East & Africa Inhalation CDMO Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza

11.1.1 Lonza Company Details

11.1.2 Lonza Business Overview

11.1.3 Lonza Inhalation CDMO Introduction

11.1.4 Lonza Revenue in Inhalation CDMO Business (2021–2026)

11.1.5 Lonza Recent Development

11.2 Vectura

11.2.1 Vectura Company Details

11.2.2 Vectura Business Overview

11.2.3 Vectura Inhalation CDMO Introduction

11.2.4 Vectura Revenue in Inhalation CDMO Business (2021–2026)

11.2.5 Vectura Recent Development

11.3 Iconovo

11.3.1 Iconovo Company Details

11.3.2 Iconovo Business Overview

11.3.3 Iconovo Inhalation CDMO Introduction

11.3.4 Iconovo Revenue in Inhalation CDMO Business (2021–2026)

11.3.5 Iconovo Recent Development

11.4 CritiTech

11.4.1 CritiTech Company Details

11.4.2 CritiTech Business Overview

11.4.3 CritiTech Inhalation CDMO Introduction

11.4.4 CritiTech Revenue in Inhalation CDMO Business (2021–2026)

11.4.5 CritiTech Recent Development

11.5 Hovione

11.5.1 Hovione Company Details

11.5.2 Hovione Business Overview

11.5.3 Hovione Inhalation CDMO Introduction

11.5.4 Hovione Revenue in Inhalation CDMO Business (2021–2026)

11.5.5 Hovione Recent Development

11.6 Recipharm

11.6.1 Recipharm Company Details

11.6.2 Recipharm Business Overview

11.6.3 Recipharm Inhalation CDMO Introduction

11.6.4 Recipharm Revenue in Inhalation CDMO Business (2021–2026)

11.6.5 Recipharm Recent Development

11.7 Aptar Pharma

11.7.1 Aptar Pharma Company Details

11.7.2 Aptar Pharma Business Overview

11.7.3 Aptar Pharma Inhalation CDMO Introduction

11.7.4 Aptar Pharma Revenue in Inhalation CDMO Business (2021–2026)

11.7.5 Aptar Pharma Recent Development

11.8 Kindeva

11.8.1 Kindeva Company Details

11.8.2 Kindeva Business Overview

11.8.3 Kindeva Inhalation CDMO Introduction

11.8.4 Kindeva Revenue in Inhalation CDMO Business (2021–2026)

11.8.5 Kindeva Recent Development

11.9 Sanner

11.9.1 Sanner Company Details

11.9.2 Sanner Business Overview

11.9.3 Sanner Inhalation CDMO Introduction

11.9.4 Sanner Revenue in Inhalation CDMO Business (2021–2026)

11.9.5 Sanner Recent Development

11.10 Particle Sciences

11.10.1 Particle Sciences Company Details

11.10.2 Particle Sciences Business Overview

11.10.3 Particle Sciences Inhalation CDMO Introduction

11.10.4 Particle Sciences Revenue in Inhalation CDMO Business (2021–2026)

11.10.5 Particle Sciences Recent Development

11.11 Experic

11.11.1 Experic Company Details

11.11.2 Experic Business Overview

11.11.3 Experic Inhalation CDMO Introduction

11.11.4 Experic Revenue in Inhalation CDMO Business (2021–2026)

11.11.5 Experic Recent Development

11.12 Enteris Biopharma

11.12.1 Enteris Biopharma Company Details

11.12.2 Enteris Biopharma Business Overview

11.12.3 Enteris Biopharma Inhalation CDMO Introduction

11.12.4 Enteris Biopharma Revenue in Inhalation CDMO Business (2021–2026)

11.12.5 Enteris Biopharma Recent Development

11.13 Catalent

11.13.1 Catalent Company Details

11.13.2 Catalent Business Overview

11.13.3 Catalent Inhalation CDMO Introduction

11.13.4 Catalent Revenue in Inhalation CDMO Business (2021–2026)

11.13.5 Catalent Recent Development

11.14 HCmed

11.14.1 HCmed Company Details

11.14.2 HCmed Business Overview

11.14.3 HCmed Inhalation CDMO Introduction

11.14.4 HCmed Revenue in Inhalation CDMO Business (2021–2026)

11.14.5 HCmed Recent Development

11.15 Ritedose

11.15.1 Ritedose Company Details

11.15.2 Ritedose Business Overview

11.15.3 Ritedose Inhalation CDMO Introduction

11.15.4 Ritedose Revenue in Inhalation CDMO Business (2021–2026)

11.15.5 Ritedose Recent Development

11.16 Bespak

11.16.1 Bespak Company Details

11.16.2 Bespak Business Overview

11.16.3 Bespak Inhalation CDMO Introduction

11.16.4 Bespak Revenue in Inhalation CDMO Business (2021–2026)

11.16.5 Bespak Recent Development

11.17 Proveris

11.17.1 Proveris Company Details

11.17.2 Proveris Business Overview

11.17.3 Proveris Inhalation CDMO Introduction

11.17.4 Proveris Revenue in Inhalation CDMO Business (2021–2026)

11.17.5 Proveris Recent Development

11.18 Bend Bioscience

11.18.1 Bend Bioscience Company Details

11.18.2 Bend Bioscience Business Overview

11.18.3 Bend Bioscience Inhalation CDMO Introduction

11.18.4 Bend Bioscience Revenue in Inhalation CDMO Business (2021–2026)

11.18.5 Bend Bioscience Recent Development

11.19 Renejix

11.19.1 Renejix Company Details

11.19.2 Renejix Business Overview

11.19.3 Renejix Inhalation CDMO Introduction

11.19.4 Renejix Revenue in Inhalation CDMO Business (2021–2026)

11.19.5 Renejix Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Inhalation CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Metered Dose Inhalers (MDIs)

Table 3. Key Players of Dry Powder Inhalers (DPIs)

Table 4. Key Players of Soft Mist Inhalers (SMIs)

Table 5. Key Players of Others

Table 6. Global Inhalation CDMO Market Size Growth Rate by Technology Platform (US$ Million): 2021 vs 2025 vs 2032

Table 7. Key Players of Propellant-based Inhalation Technology Platform

Table 8. Key Players of Dry Powder Inhalation Technology Platform

Table 9. Key Players of Nebulization Technology Platform

Table 10. Key Players of Combined Inhalation Technology Platform

Table 11. Global Inhalation CDMO Market Size Growth Rate by Service Stage (US$ Million): 2021 vs 2025 vs 2032

Table 12. Key Players of Preclinical Development CDMO

Table 13. Key Players of Clinical Stage CDMO

Table 14. Key Players of Commercial Production CDMO

Table 15. Key Players of One-stop Full-cycle CDMO

Table 16. Global Inhalation CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Inhalation CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 18. Global Inhalation CDMO Market Size by Region (US$ Million), 2021–2026

Table 19. Global Inhalation CDMO Market Share by Region (2021–2026)

Table 20. Global Inhalation CDMO Forecasted Market Size by Region (US$ Million), 2027–2032

Table 21. Global Inhalation CDMO Market Share by Region (2027–2032)

Table 22. Inhalation CDMO Market Trends

Table 23. Inhalation CDMO Market Drivers

Table 24. Inhalation CDMO Market Challenges

Table 25. Inhalation CDMO Market Restraints

Table 26. Global Inhalation CDMO Revenue by Players (US$ Million), 2021–2026

Table 27. Global Inhalation CDMO Market Share by Players (2021–2026)

Table 28. Global Top Inhalation CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Inhalation CDMO Revenue, 2025

Table 29. Ranking of Global Top Inhalation CDMO Companies by Revenue (US$ Million) in 2025

Table 30. Global 5 Largest Players Market Share by Inhalation CDMO Revenue (CR5 and HHI), 2021–2026

Table 31. Global Key Players of Inhalation CDMO, Headquarters and Area Served

Table 32. Global Key Players of Inhalation CDMO, Products and Applications

Table 33. Global Key Players of Inhalation CDMO, Date of General Availability (GA)

Table 34. Mergers and Acquisitions, Expansion Plans

Table 35. Global Inhalation CDMO Market Size by Type (US$ Million), 2021–2026

Table 36. Global Inhalation CDMO Revenue Market Share by Type (2021–2026)

Table 37. Global Inhalation CDMO Forecasted Market Size by Type (US$ Million), 2027–2032

Table 38. Global Inhalation CDMO Revenue Market Share by Type (2027–2032)

Table 39. Global Inhalation CDMO Market Size by Application (US$ Million), 2021–2026

Table 40. Global Inhalation CDMO Revenue Market Share by Application (2021–2026)

Table 41. Global Inhalation CDMO Forecasted Market Size by Application (US$ Million), 2027–2032

Table 42. Global Inhalation CDMO Revenue Market Share by Application (2027–2032)

Table 43. North America Inhalation CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. North America Inhalation CDMO Market Size by Country (US$ Million), 2021–2026

Table 45. North America Inhalation CDMO Market Size by Country (US$ Million), 2027–2032

Table 46. Europe Inhalation CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Europe Inhalation CDMO Market Size by Country (US$ Million), 2021–2026

Table 48. Europe Inhalation CDMO Market Size by Country (US$ Million), 2027–2032

Table 49. Asia-Pacific Inhalation CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 50. Asia-Pacific Inhalation CDMO Market Size by Region (US$ Million), 2021–2026

Table 51. Asia-Pacific Inhalation CDMO Market Size by Region (US$ Million), 2027–2032

Table 52. Latin America Inhalation CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 53. Latin America Inhalation CDMO Market Size by Country (US$ Million), 2021–2026

Table 54. Latin America Inhalation CDMO Market Size by Country (US$ Million), 2027–2032

Table 55. Middle East & Africa Inhalation CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 56. Middle East & Africa Inhalation CDMO Market Size by Country (US$ Million), 2021–2026

Table 57. Middle East & Africa Inhalation CDMO Market Size by Country (US$ Million), 2027–2032

Table 58. Lonza Company Details

Table 59. Lonza Business Overview

Table 60. Lonza Inhalation CDMO Product

Table 61. Lonza Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 62. Lonza Recent Development

Table 63. Vectura Company Details

Table 64. Vectura Business Overview

Table 65. Vectura Inhalation CDMO Product

Table 66. Vectura Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 67. Vectura Recent Development

Table 68. Iconovo Company Details

Table 69. Iconovo Business Overview

Table 70. Iconovo Inhalation CDMO Product

Table 71. Iconovo Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 72. Iconovo Recent Development

Table 73. CritiTech Company Details

Table 74. CritiTech Business Overview

Table 75. CritiTech Inhalation CDMO Product

Table 76. CritiTech Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 77. CritiTech Recent Development

Table 78. Hovione Company Details

Table 79. Hovione Business Overview

Table 80. Hovione Inhalation CDMO Product

Table 81. Hovione Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 82. Hovione Recent Development

Table 83. Recipharm Company Details

Table 84. Recipharm Business Overview

Table 85. Recipharm Inhalation CDMO Product

Table 86. Recipharm Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 87. Recipharm Recent Development

Table 88. Aptar Pharma Company Details

Table 89. Aptar Pharma Business Overview

Table 90. Aptar Pharma Inhalation CDMO Product

Table 91. Aptar Pharma Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 92. Aptar Pharma Recent Development

Table 93. Kindeva Company Details

Table 94. Kindeva Business Overview

Table 95. Kindeva Inhalation CDMO Product

Table 96. Kindeva Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 97. Kindeva Recent Development

Table 98. Sanner Company Details

Table 99. Sanner Business Overview

Table 100. Sanner Inhalation CDMO Product

Table 101. Sanner Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 102. Sanner Recent Development

Table 103. Particle Sciences Company Details

Table 104. Particle Sciences Business Overview

Table 105. Particle Sciences Inhalation CDMO Product

Table 106. Particle Sciences Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 107. Particle Sciences Recent Development

Table 108. Experic Company Details

Table 109. Experic Business Overview

Table 110. Experic Inhalation CDMO Product

Table 111. Experic Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 112. Experic Recent Development

Table 113. Enteris Biopharma Company Details

Table 114. Enteris Biopharma Business Overview

Table 115. Enteris Biopharma Inhalation CDMO Product

Table 116. Enteris Biopharma Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 117. Enteris Biopharma Recent Development

Table 118. Catalent Company Details

Table 119. Catalent Business Overview

Table 120. Catalent Inhalation CDMO Product

Table 121. Catalent Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 122. Catalent Recent Development

Table 123. HCmed Company Details

Table 124. HCmed Business Overview

Table 125. HCmed Inhalation CDMO Product

Table 126. HCmed Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 127. HCmed Recent Development

Table 128. Ritedose Company Details

Table 129. Ritedose Business Overview

Table 130. Ritedose Inhalation CDMO Product

Table 131. Ritedose Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 132. Ritedose Recent Development

Table 133. Bespak Company Details

Table 134. Bespak Business Overview

Table 135. Bespak Inhalation CDMO Product

Table 136. Bespak Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 137. Bespak Recent Development

Table 138. Proveris Company Details

Table 139. Proveris Business Overview

Table 140. Proveris Inhalation CDMO Product

Table 141. Proveris Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 142. Proveris Recent Development

Table 143. Bend Bioscience Company Details

Table 144. Bend Bioscience Business Overview

Table 145. Bend Bioscience Inhalation CDMO Product

Table 146. Bend Bioscience Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 147. Bend Bioscience Recent Development

Table 148. Renejix Company Details

Table 149. Renejix Business Overview

Table 150. Renejix Inhalation CDMO Product

Table 151. Renejix Revenue in Inhalation CDMO Business (US$ Million), 2021–2026

Table 152. Renejix Recent Development

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

Table 156. Authors List of This Report

List of Figures

Figure 1. Inhalation CDMO Picture

Figure 2. Global Inhalation CDMO Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Inhalation CDMO Market Share by Type: 2025 vs 2032

Figure 4. Metered Dose Inhalers (MDIs) Features

Figure 5. Dry Powder Inhalers (DPIs) Features

Figure 6. Soft Mist Inhalers (SMIs) Features

Figure 7. Others Features

Figure 8. Global Inhalation CDMO Market Size Comparison by Technology Platform (US$ Million), 2021–2032

Figure 9. Propellant-based Inhalation Technology Platform Features

Figure 10. Dry Powder Inhalation Technology Platform Features

Figure 11. Nebulization Technology Platform Features

Figure 12. Combined Inhalation Technology Platform Features

Figure 13. Global Inhalation CDMO Market Size Comparison by Service Stage (US$ Million), 2021–2032

Figure 14. Preclinical Development CDMO Features

Figure 15. Clinical Stage CDMO Features

Figure 16. Commercial Production CDMO Features

Figure 17. One-stop Full-cycle CDMO Features

Figure 18. Global Inhalation CDMO Market Size by Application (US$ Million), 2021–2032

Figure 19. Global Inhalation CDMO Market Share by Application: 2025 vs 2032

Figure 20. Commercial Case Studies

Figure 21. Academic Research Case Studies

Figure 22. Others Case Studies

Figure 23. Inhalation CDMO Report Years Considered

Figure 24. Global Inhalation CDMO Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 25. Global Inhalation CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 26. Global Inhalation CDMO Market Share by Region: 2025 vs 2032

Figure 27. Global Inhalation CDMO Market Share by Players in 2025

Figure 28. Global Inhalation CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 29. The Top 10 and 5 Players Market Share by Inhalation CDMO Revenue in 2025

Figure 30. North America Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. North America Inhalation CDMO Market Share by Country (2021–2032)

Figure 32. United States Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Canada Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Europe Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Europe Inhalation CDMO Market Share by Country (2021–2032)

Figure 36. Germany Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. France Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. U.K. Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Italy Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Russia Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Ireland Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Asia-Pacific Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Asia-Pacific Inhalation CDMO Market Share by Region (2021–2032)

Figure 44. China Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Japan Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. South Korea Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Southeast Asia Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. India Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Australia & New Zealand Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Latin America Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Latin America Inhalation CDMO Market Share by Country (2021–2032)

Figure 52. Mexico Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Brazil Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Middle East & Africa Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Middle East & Africa Inhalation CDMO Market Share by Country (2021–2032)

Figure 56. Israel Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. Saudi Arabia Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. UAE Inhalation CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 59. Lonza Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 60. Vectura Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 61. Iconovo Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 62. CritiTech Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 63. Hovione Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 64. Recipharm Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 65. Aptar Pharma Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 66. Kindeva Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 67. Sanner Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 68. Particle Sciences Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 69. Experic Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 70. Enteris Biopharma Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 71. Catalent Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 72. HCmed Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 73. Ritedose Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 74. Bespak Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 75. Proveris Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 76. Bend Bioscience Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 77. Renejix Revenue Growth Rate in Inhalation CDMO Business (2021–2026)

Figure 78. Bottom-up and Top-down Approaches for This Report

Figure 79. Data Triangulation

Figure 80. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions